Press releases
- May 29, 2013
Alethia Biotherapeutics Announce Entry into Licensing and Research Agreements for its Inhibitor of EMT with IBC Generium
- May 16, 2013
Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT
- February 28, 2013
Alethia Biotherapeutics Announces Notice of Allowance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT
- February 19, 2013
Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15
- November 1, 2012
Alethia Biotherapeutics Closes a $4.7 Million Financing to Advance its Bone Antiresorptive Program